title: [Oxaliplatin plus capecitabine for advanced gastric cancer: report of 38 cases].
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of the combination chemotherapy of oxaliplatin with capecitabine(XELOX)in patients with advanced gastric cancer.
  
  
  METHODS
  Thirty-eight advanced gastric cancer patients who received XELOX regimen during 2004-2009 were analyzed retrospectively. The combination chemotherapy included oxaliplatin as 2-hour infusion on day 1 and capecitabine po bid on days 1 to 14. Treatment was repeated every 3 weeks.
  
  
  RESULTS
  XELOX regime was applied as first-line therapy in 34 patients and as second-line therapy in 4 patients. After three cycles of chemotherapy, the outcomes in 32 patients who received XELOX as the first-line therapy included partial response (n = 8,25.0%), stable disease (n=14,43.8%), and progressive disease (n=10, 31.2%); no patient achieved complete response. The median time to progression and overall survival time were 7.0 months (95% CI: 4.5-9.5 months) and 12 months (95% CI: 9.8-14.2 months), respectively. One-year and two-year survival rates were 40.6% and 23.7%, respectively. Grade 3-4 toxicities including neutropenia (10.5%), thrombocytopenia (2.6%), nausea (7.9%), and vomiting (5.3%)were noted in a few patients.
  
  
  CONCLUSIONS
  XELOX regimen can be effectively and safely applied as first-line treatment for advanced gastric cancer patients.
authors.affiliation: Department of Medical Oncology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Guan
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.forename: Lin
authors.initials: L
authors.lastname: Zhao
authors.forename: Chun-mei
authors.initials: CM
authors.lastname: Bai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010071:Oxaloacetates; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil